New scan could spot dangerous prostate cancer without needle biopsy
NCT ID NCT03471650
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a special PET/CT scan using a radioactive tracer called 18F-DCFPyL can better detect aggressive prostate cancer in men with elevated PSA levels. About 150 men with PSA between 2-10 ng/mL and no prior biopsy will receive the scan before their standard biopsy. The goal is to see if the scan is more accurate than PSA alone at identifying cancers that need treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-DCFPyL (a radioactive tracer for PET/CT imaging)
What this could lead to
If successful, this scan could become a more accurate, non-invasive way to detect aggressive prostate cancer early, reducing unnecessary biopsies.
What could go wrong
This is a single-center, phase II study with only 150 men, so results may not apply to everyone. The scan may not be better than current methods and could still miss some cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SKCCC
Baltimore, Maryland, 21287, United States